Growth fraction as a prognostic factor in endometrial carcinoma detected by the monoclonal antibody Ki-S1;Die proliferationsrate als prognosekriterium beim endometriumkarzinom - Eine immunohistochemische analyse mit dem monoklonalen antikorper KI-S1

Zentralblatt fur Gynakologie

Volumn 119, Issue 7, 1997, Pages 334-342

  Backe, Jael ^a   Gassel, A M ^b   Muller T ^a   Schon S ^a   Kaesemann, H ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Geburtshilflich Gynakol Abteilung   (Germany)

Author keywords

Endometrial carcinoma; Grading; Growth fraction; Myometrial invasion; Prognosticators

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI S1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030818050     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Baltzer J, Maaßen V: Präneoplasien und Neoplasien des Endometriums. In: Klinik der Frauenheilkunde und Geburtshilfe Bd. 11. Spezielle gynäkologische Onkologie. Hrsg.: Schmidt-Matthiesen H, München - Wien - Baltimore: Urban & Schwarzenberg 1991, 207-251
2. Carriaga MT, Henson DE: The Histologic grading of cancer. Cancer 75 (1995) 406-421
3. Coleman RL, Schink JC, Miller DS, Bauer KD: DNA Flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol 50 (1993) 20-24
4. Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer 71 (1993) 1467-1470
5. Dallenbach F: Proliferationsmarker bei Endometriumkarzinomen verschiedener Histogenese: Vergleich immunhistologischer Untersuchungen an Kryostat- und Paraffinschnitten. Verh Dtsch Ces Path 75 (1991) 375
6. Dallenbach-Hellweg G: Histopathology of the endometrium. Berlin - Heidelberg: Springer, 4. Aufl. 1987
7. Dallenbach-Hellweg G, Lang-Averous G, Hahn U: The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS Suppl 23 (1991) 91-99
8. FIGO stages: 1988 revision. Gynecol Oncol 35 (1989) 125-127
9. Garcia RL, Coltrera RL, Gown AM: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 134 (1989) 733-739
10. Grulich D, Hagen A, Morack G: Prognosefaktoren und Behandlungsereebnisse beim Endometriumkarzinom. Zentralbl Gynakol 118 (1996) 154-163
11. Grund C: Medas, Statistikprogramm für Medizin und Biowissenschaften, Würzburg 1993
12. Gusberg SB: Virulence Factors in Endometrial Cancer. Cancer 71 (1993) 1464-1466
13. Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H: Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol 84 (1994) 979-982
14. Kleine W, Maier T, Geyer H, Pfleiderer A: Estrogen and progesteron receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38 (1990) 59-65
15. Kokeguchi S, Hayase R, Sekiba K: Proliferative activity in normal endometrium and endometrial carcinoma measured by immunohistochemistry using Ki-67 and anti-DNA polymerase an antibody, and by flow cytometry. Acta Med Okayama 46 (1992) 113-121
16. Kosary CLK: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecologic system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10 (1994) 31-46
17. Kreipe H, Heidebrecht HJ, Hansen S, Röhlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R: A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142 (1993) 3-10
18. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M, Parwaresch R: Determination of the growth fraction in Non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 142 (1993) 1689-1694
19. Mittal KR, Schwartz PE, Barwick KW: Architectural (FIGO) grading, nuclear grading and other prognostic indicators in stage I endometrial carcinoma with identification of high-risk and low-risk groups-Cancer 61 (1988) 538-545
20. Mitze M, Weikel W, Brumm C, Lippold R, Knapstein PG: Einfluß der Proliferationsrate auf den Krankheitsverlauf von nodalnegativen Mammakarzinomen. Geburtshilfe Frauenheilkd 55 (1995) 299-305
21. Nielsen AL, Nyholm HCJ: Proliferating cell nuclear antigen in endometrial adenocarcinoma of endometrioid type correlated with histologic grade, stage, previous hormonal treatment, and survival. Hum Pathol 24 (1993) 1003-1007
22. Nielsen AL, Nyholm HCJ: Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumours from patients with and without previous oestrogen therapy. J Pathol 171 (1993) 199-205
23. Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Thorpe SM: Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol 12 (1993) 246-252
24. Pfleiderer A: Das Endometriumkarzinom. Neue Ansätze und Überlegungen zur Therapie. Bericht von der Sitzung der AGO im August 1994. Frauenarzt 36 (1995) 853-855
25. Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (1RS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8 (1987) 138-140
26. Schmidt-Matthiesen H, Bastert G: Gynäkologische Onkologie. Stuttgart: Schattauer 1995
27. Schneider ML: Morphologische Prognosekriterien beim Endometriumkarzinom unter besonderer Berücksichtigung des Kerngradings. Geburtshilfe Frauenheilkd 46 (1986) 267-277
28. Silverberg SG, Kurman RJ: Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. In: Armed Forces Institute of Pathology. Atlas of Tumor Patholosy 3.3, Washington D.C. USA 1992
29. Vecek N, Nola M, Marusic M, Ilic J, Babic D, Petrovecki M, Nikolic S, Marinovic T, Jukic D, Vecek N: Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 73 (1994) 730-733
30. Wilkinson N, Buckley CH, Chawner L, et al.: Nucleolar organizer regions in normal, hyperplastic and neoplastic endometria. Int J Gynecol Pathol 9 (1990) 55-59
31. World Health Organization: Histological Typing of Female Genital Tract Tumours. International Histological Classification of Tumours, 13 (1994)
32. Yabushita H, Masuda T, Sawaguchi K, et al.: Growth potential of endometrial cancers assessed by a Ki-67 Ag/DNA dual flowcytometric assay. Gynecol Oncol 44 (1992) 263-267